Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 7/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.66 |
| ▸ | MAPT | P10636 | 8/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237828 | 0.94 | OPRL1 (0.61) | OPRL1OPRM1MAPTMAPK1MEN1 | |
| SCHEMBL4855464 | 0.93 | OPRL1 (0.66) | OPRL1OPRM1MAPTMAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL4854811 | 0.92 | OPRL1 (0.67) | OPRL1OPRM1MAPTMAPK1MEN1 | |
| Citric Acid SCHEMBL4858328 | 0.90 | OPRL1 (0.55) | OPRL1OPRM1MAPTMAPK1MEN1 | |
| SCHEMBL4855428 | 0.89 | OPRL1 (0.66) | OPRL1OPRM1MAPTMEN1KMT2A | |
| SCHEMBL5343485 | 0.88 | OPRL1 (0.74) | OPRL1OPRM1MAPTMAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL4852102 | 0.88 | OPRL1 (0.67) | OPRL1OPRM1MAPTMEN1KMT2A | |
| SCHEMBL4857895 | 0.88 | OPRL1 (0.73) | OPRL1OPRM1MAPTMAPK1MEN1 | |
| Hydrochloric Acid SCHEMBL5336823 | 0.87 | OPRL1 (0.74) | OPRL1OPRM1MAPTMAPK1MEN1 | |
| SCHEMBL4852054 | 0.84 | OPRL1 (0.55) | OPRL1OPRM1MAPTMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560809-B1 | CYCLOHEXYLUREA DERIVATIVES | GRUENENTHAL GMBH (DE) | 2007-08-22 | — | — | EP | claimed |
| US-7348354-B2 | Cyclohexylurea compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-7173045-B2 | 4-aminomethyl-1-aryl-cyclohexylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-06 | — | — | US | disclosed |
| US-20050261358-A1 | antinociceptive agent of opioid-receptor for treating pain; tert-aminecyclohexyl-urea, or -thiourea, or -amide derivatives; 1-(4-dimethylamino-4-phenylcyclohexyl)-3-(3-phenylpropyl)urea hydrochloride; stereoisomers; racemic mixtures | GRUENENTHAL GMBH (DE) | 2005-11-24 | — | — | US | disclosed |
| US-20050245593-A1 | 4-Aminomethyl-1-aryl-cyclohexylamine compounds | GRUENENTHAL GMBH (DE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245593-A1 | 4-Aminomethyl-1-aryl-cyclohexylamine compounds | HNMT, PNMT, INMT | OPRL1 378/4885OPRM1 69/4885MAPT 956/4885 |
| US-20050261358-A1 | antinociceptive agent of opioid-receptor for treating pain; tert-aminecyclohexyl-urea, or -thiourea, or -amide derivatives; 1-(4-dimethylamino-4-phenylcyclohexyl)-3-(3-phenylpropyl)urea hydrochloride; stereoisomers; racemic mixtures | OPRL1, OPRM1, OGFRL1 | OPRL1 1/4885OPRM1 2/4885MAPT 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.